Table 1.
Correlations between ECT2 expression and clinic-pathological features of 120 breast cancer patients in immunohistochemistry chip (HBreD145Su01)
Variables | N | ECT2 expression | P value | |
---|---|---|---|---|
< 8 (low expression) | ≥ 8 (high expression) | |||
Age | 0.224a | |||
< Median(51) | 57 | 28 | 29 | |
≥ Median (51) | 63 | 24 | 39 | |
Tumor location | 0.961a | |||
Left | 58 | 25 | 33 | |
Right | 62 | 27 | 35 | |
Grade | 0.073a | |||
Grade 1 | 25 | 16 | 9 | |
Grade 2 | 90 | 44 | 56 | |
Stage | 0.043a | |||
Stage I–II | 75 | 37 | 38 | |
Stage III–IV | 43 | 13 | 30 | |
Subtype | 0.0041a | |||
Luminal | 89 | 46 | 43 | |
Her2 enriched | 13 | 4 | 9 | |
Basal | 18 | 2 | 16 |
aPearson Chi-square test